Skip to content
Company Analysis

Novo Nordisk A/S NVO

A comprehensive view of key metrics, scores, and financial health for Novo Nordisk A/S

Overview of Novo Nordisk A/S

NVO NYQ
Healthcare Drug Manufacturers - General Large Cap
Novo Nordisk A/S (NVO), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $37.96, about 371.9% undervalued vs fair value, -52.6% 1Y return, placing in the top 10% of its sector.
$37.96
-0.16%
As of March 13, 2026
Previous close • Vol 90d: 62.0%
52-Week Range
Market Cap
$172.26B
Enterprise Value
$276.75B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Novo Nordisk A/S.

Top Beats

Quick Facts

Website https://www.novonordisk.com
HQ Bagsvaerd
Employees 68,794
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$166
$179
$193
Current: $37.96 +372% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$309.1B
6.4%%
Gross Profit
$250.3B
1.8%%
R&D Expense
$52.0B
8.3%%
Operating Income (EBIT)
$134.7B
4.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
88.4%
Good

Good cash conversion

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$53.2B
183.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
0/4
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Novo Nordisk A/S's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
77
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
92
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing NVO's balance between Growth (32.5%), Profitability (43.0%), and Safety (24.5%). Growth 33% Safety 25% Profitability 43%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

62th percentile vs peers
63
Key Signals
Revenue CAGR 3Y 20.4% 84p Rev Growth YoY 6.4% 63p EPS CAGR 3Y 23.5% 81p EPS Growth YoY 1.8% 42p TSR -27.3% 20p
Strengths
  • Revenue Cagr 3Y in top 20% of peers (20.4%, 84th percentile)
  • Eps Cagr 3Y in top 20% of peers (23.5%, 81th percentile)
  • Interest Coverage Ratio in top 20% of peers (32.03, 90th percentile)
  • Superior capital returns - 3 return metrics above peer median
Risks

No significant risks identified for this axis.

Profitability

82th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

47th percentile vs peers
47
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Novo Nordisk A/S.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$179.14
- - -
+371.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info